Biocon is currently trading at RS 337.25, up by 4.15 points or 1.25% from its previous closing of RS 333.10 on the BSE.

The stock opened at RS 337.95 and reached a high of RS 338.75 and a low of RS 334.65. A total of 43,957 shares have been traded so far.

Biocon, categorized under the BSE group 'A' with a face value of RS 5, hit a 52-week high of RS 404.60 on 21-Jan-2025 and a 52-week low of RS 244.40 on 20-Mar-2024. Over the past week, the stock's high and low stood at RS 338.75 and RS 290.80, respectively. The company's market capitalization is RS 40,400.19 crore.

In terms of shareholding, promoters hold 60.64% of the company, while institutions and non-institutions hold 21.02% and 18.34%, respectively.

Meanwhile, Biocon’s subsidiary, Biocon Biologics (BBL), has entered into a strategic collaboration with Civica, Inc., a not-for-profit pharmaceutical firm, to enhance access and affordability of Insulin Aspart in the U.S. Under this agreement, Biocon Biologics will supply the drug substance for Insulin Aspart, while Civica will manufacture and commercialize the drug in the U.S. following development and clinical trials. No technology transfer is involved in the deal.

Additionally, Biocon Biologics' own Insulin Aspart drug product is currently under review by the U.S. FDA. The collaboration aims to support the 38.4 million people living with diabetes in the U.S., a figure that accounts for 11.6% of the population, with an additional 97.6 million identified as prediabetic.

Biocon is India's largest and Asia’s leading biotechnology firm, specializing in biopharmaceuticals and research services, offering affordable healthcare solutions for chronic diseases globally.